Claire S. Reader

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Kate M. Moore · 2 shared papers, 2019–2020 · strength 0.17
   • Paper Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. DOI 10.7150/thno.38702↗
   • Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
2. John F. Marshall · 2 shared papers, 2019–2020 · strength 0.17
   • Paper Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. DOI 10.7150/thno.38702↗
   • Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
3. Sara Maria David Trabulo · 1 shared paper, 2020 · strength 0.10
   • Paper Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. DOI 10.7150/thno.38702↗
4. Nicholas Fraser Brown · 1 shared paper, 2020 · strength 0.10
   • Paper Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. DOI 10.7150/thno.38702↗
5. Syed Haider · 1 shared paper, 2019 · strength 0.07
   • Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
6. Colin William Steele · 1 shared paper, 2019 · strength 0.07
   • Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
7. Peter J. Bailey · 1 shared paper, 2019 · strength 0.07
   • Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
8. Simon T. Barry · 1 shared paper, 2019 · strength 0.07
   • Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
9. Nigel Balfour Jamieson · 1 shared paper, 2019 · strength 0.07
   • Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
10. Rita Teresa Lawlor · 1 shared paper, 2019 · strength 0.07
    • Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
11. Claude Chelala · 1 shared paper, 2019 · strength 0.07
    • Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
12. Jennifer P. Morton · 1 shared paper, 2019 · strength 0.07
    • Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
13. David Kuang-Fu Chang · 1 shared paper, 2019 · strength 0.07
    • Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
14. Owen James Sansom · 1 shared paper, 2019 · strength 0.07
    • Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
15. Hemant Mahendrakumar Kocher · 1 shared paper, 2019 · strength 0.07
    • Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
16. Andrew Victor Biankin · 1 shared paper, 2019 · strength 0.07
    • Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗
17. Aldo Scarpa Scarpa · 1 shared paper, 2019 · strength 0.07
    • Paper The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. DOI 10.1002/path.5320↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.